Abiraterone prodrugs
AssigneePropella Therapeutics, Inc.
InventorsMatthew J. Sharp, William R. Moore, Jr.
Life of this patent
Estimating the term…
Abstract
Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, an androgen receptor driven cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
Claims21
A method of treating a sex hormone dependent or androgen receptor driven cancer in a non-castrated subject in need thereof, the method comprising parenterally administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an abiraterone prodrug, and further administering to the subject a bone protecting agent, wherein the subject is characterized as having prostate cancer with bone metastasis.
Dependencies are inferred from the claim text.